Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators.

N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.

2.

Selected metabolites of neutrophils in patients with 2-type diabetes complicated and non complicated with diabetic foot syndrome during colonization of E. coli toxin.

Loś T, Torres K, Bojarska-Łoś M, Torres A, Staśkiewicz G, Maciejewski R, Roliński J, Radej S, Klimowicz E.

Folia Histochem Cytobiol. 2009 Jan;47(3):411-4. doi: 10.2478/v10042-008-0116-2.

3.

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team.

Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6.

PMID:
19501900

Supplemental Content

Loading ...
Support Center